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MetastasisThis manuscript provides an overview of the dynamic interactions which play an important role in regulating
cancer cell functions. We describe and discuss, primarily, those interactions which involve membrane type-1
matrix metalloproteinase (MT1-MMP), its physiological inhibitor tissue inhibitor of metalloproteinases-2
(TIMP-2), furin-like proprotein convertases and the low density lipoprotein-related protein 1 (LRP1) signaling
scavenger receptor. The interaction among these cellular proteins controls the efﬁciency of the activation of
MT1-MMP and the unorthodox intracellular signaling which is generated by the catalytically inert complex of
MT1-MMP with TIMP-2 and which plays a potentially important role in the migration of cancer cells. Our in-
depth understanding of these cellular mechanismsmay provide the key to solving the puzzling TIMP-2 paradox.
This unsolved paradox arises from the fact that TIMP-2 is a powerful inhibitor of MMPs includingMT1-MMP, but
at the same time high levels of TIMP-2 positively correlate with an unfavorable prognosis in cancer patients.
Solving the TIMP-2 paradox may lead to solving a similar PAI-1 paradox and produce a clearer understanding of
the biochemical mechanisms which control the functionality of the urokinase-type plasminogen activator•ur-
okinase receptor•plasminogen activator inhibitor type-1 (uPAR•uPA•PAI-1) system in cancer.© 2009 Elsevier B.V. All rights reserved.1. Matrix metalloproteinases (MMPs)Historically, interstitial collagenase (MMP-1) was the ﬁrst identi-
ﬁed member of the now extensive matrix metalloproteinase (MMP)
family. MMP-1 was initially discovered in the course of studying
collagen remodeling during the metamorphosis of a tadpole into a
frog and much later the presence of this enzyme was conﬁrmed in
humans [1,2]. Because collagens, especially type I collagen, represent
the major structural proteins of all tissues and serve as the main
barrier to migrating cells, more than three decades ago an innovative
hypothesis was postulated and this hypothesis has now been
validated. According to this hypothesis, collagenolytic enzymes
including MMP-1 play pivotal roles in multiple physiologic and
especially, pathologic processes, which involve both extensive and
aberrant collagenolysis. Recent scientiﬁc discoveries have vastly
expanded our knowledge of MMPs' structures and functions. These
discoveries directly implicate a number of the individual MMPs,
including MMP-1, in multiple diseases of the cardiovascular, pulmon-
ary, renal, endocrine, gastrointestinal, musculoskeletal, visual, and
hematopoietic systems in humans.
MMPs belong to a zinc endopeptidase, metzincin superfamily [3].
This superfamily is distinguished from other proteinases by the
presence of a strictly conserved HEXXHXXGXX(H/D) histidine
sequence motif. This motif exhibits three histidine residues thatll rights reserved.chelate the active site zinc and also a canonical methionine residue
which is the C-terminal to the conserved histidine sequence. The
canonical methionine is part of a tight 1,4-beta-turn that loops the
polypeptide chain beneath the catalytic zinc ion, forming a hydro-
phobic ﬂoor to the zinc ion binding site. The metzincin family is
normally divided into four sub-families: seralysins, astacins, adama-
lysins [ADAMs (proteins with a disintegrin and a metalloproteinase
domain) and ADAM-TS (ADAMwith thrombospondin-likemotif)] and
MMPs. Although our knowledge of MMP biology is rapidly expanding,
we do not as yet understand precisely how these enzymes regulate
various cellular functions.
The human MMP family is comprised of 24 currently known zinc-
containing enzymes which share several functional domains. MMPs
are often referred to by a descriptive name such as gelatinases (MMP-
2 and MMP-9) and collagenases [MMP-1, MMP-8, MMP-13, MMP-14/
membrane type-1 matrix metalloproteinase (MT1-MMP) and, some
what conclusively, MMP-18] and this name is generally based on a
preferred substrate. Collagenases are the only known mammalian
enzymes capable of degrading triple-helical ﬁbrillar collagen into
distinctive 3/4 and 1/4 fragments. An additional and widely accepted
MMP numbering system based on the order of discovery is also in use
(Fig. 1) [4,5].
MMPs may be described as multifunctional enzymes capable of
cleaving the extracellular matrix components (collagens, laminin,
ﬁbronectin, vitronectin, aggrecan, enactin, versican, perlecan, tenas-
cin, elastin and many others), growth factors, cytokines and cell
surface-associated adhesion and signaling receptors. Because of their
Fig. 1. MMP family. The structure of MMPs is made up of the following domains: 1) a signal peptide; directs MMPs to the secretory or plasma membrane insertion pathway; 2) a
prodomain; confers latency to MMPs, 3) a catalytic domain with the active site zinc atom; 4) a hemopexin-like domain; in coordination with the catalytic domain controls the
interactions with substrates, and 5) a ﬂexible hinge region; links the catalytic and the hemopexin domain and provides each domain mobility relative to the other. The membrane-
type MMPs contain an additional transmembrane domain and a short cytoplasmic tail domain (MT1-MMP/MMP-14, MMP-15, MMP-16 and MMP-24) or a glycosylphosphatidyl
inositol linkage (MMP-17 and MMP-25) to be tethered to the cell surface. MMP-2 and MMP-9 contain ﬁbronectin-like type II repeats which assist in collagen substrate binding. A
hemopexin domain is absent inMMP-7 andMMP-26. MT-MMPs (in addition to several otherMMPs) exhibit the RXKRmotif in the C-terminal region of the inhibitory prodomain and,
therefore, are activated by furin.
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microenvironment, cellular MMPs are expressed in small amounts,
and their cellular localization and activity are tightly controlled, either
positively or negatively, at both the transcriptional and the post-
transcriptional levels by cytokines, including interleukins (IL-1, IL-4
and IL-6), growth factors (epidermal growth factor, hepatocyte
growth factor and transforming growth factor-β), and tumor necrosis
factor-α [6,7]. In a feedback loop, some of these regulatory factors
themselves are proteolytically activated or inactivated by the
individual MMPs [8].
MMPs are synthesized as latent zymogens. The active site zinc of
the MMP catalytic domain is coordinated with the three histidines of
the active site and with the cysteine of the “cysteine switch” motif ofthe N-terminal prodomain [9]. To become functionally potent
proteinases, the zymogens of MMPs require proteolytic activation. In
the process of this activation, the N-terminal inhibitory prodomain is
removed and the catalytic site of the emerging enzyme becomes
liberated and exposed. The activation of MMPs may occur both
intracellularly and extracellularly [10,11]. MMPs including MMP-11,
MMP-28 and several MT-MMPs with the furin-cleavagemotif RXK/RR
in their propeptide sequence are normally activated in the trans-Golgi
network by serine proteinases such as furin and certain other
members of the proprotein convertase family. Activation of MMPs
which are secreted in the extracellular milieu is frequently mediated
by serine proteases, including plasmin, by the membrane-type MMPs
(e.g., activation of the latent soluble MMP-2 proenzyme by MT1-
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latent soluble enzymes of MMP-1 and MMP-9 by the soluble MMP-3
enzyme).
With the exception of the activated MMP-7 andMMP-26 enzymes,
which are represented by the catalytic domain alone, all other MMPs
have a C-terminal hemopexin-like domain. This domain regulates the
activity and the speciﬁcity of the catalytic domain function. The
hemopexin domain is separated from the catalytic domain by a
ﬂexible hinge region. Membrane-tethered MMPs are distinguished
from soluble MMPs by an additional transmembrane domain and a
short cytoplasmic tail (MMP-14/MT1-MMP, MMP-15/MT2-MMP,
MMP-16/MT3-MMP and MMP-24/MT5-MMP). In contrast to these
four MT-MMPs, MMP-17/MT4-MMP and MMP-25/MT6-MMP are
attached to the cell membrane via a glycosylphosphatidyl inositol
(GPI) anchor (Fig. 1). Historically, MMPs were initially characterized
by their extensive ability to degrade extracellular matrix proteins
including collagens, laminin, ﬁbronectin, vitronectin, aggrecan, enac-
tin, tenascin, elastin, and proteoglycans. More recently, it has been
recognized that MMPs cleave in addition to the extracellular matrix
components, many other protein types including cytokines and cell
adhesion signaling receptors.Fig. 2.Modular domain structure of furin and six related proprotein convertases (PCs). The A
terminal signal peptide, which directs proteins into the secretory pathway, (2) a prodom
intramolecular chaperone for proper folding, (3) a catalytic domainwith the active site that e
domain that regulates enzyme stability, and (5) a C-terminal domain that contains membraBecause the individual MMPs have overlapping substrate cleavage
preferences, MMP knockouts and inactivating mutations in individual
MMP genes in mice, with the exception of MT1-MMP, do not elicit an
easily recognized phenotype and are non-lethal, at least up to the end
of the ﬁrst few weeks after birth, suggesting a functional redundancy
among MMP family members. MT1-MMP knockout, however, has a
profound effect: MT1-MMP null mice develop dwarﬁsm, extensive
bone malformations and die before adulthood, thus supporting an
important role of MT1-MMP in collagen type I turnover [12–14]. Mice
lacking both MMP-2 and MT1-MMP die immediately after birth of
respiratory failure, abnormal blood vessels, and immature muscle
ﬁbers reminiscent of central core disease [15].
2. Tissue inhibitors of matrix metalloproteinases (TIMPs)
Once activated, MMPs are normally inhibited by tissue inhibitors of
metalloproteinases (TIMPs). Four individual species of TIMPs are
known in humans (TIMP-1, -2, -3 and -4) [16] (Fig. 2). TheMMP/TIMP
balance is believed to be a major factor in the regulation of the net
proteolytic activity of the individual MMPs. Structurally, TIMPs
contain two domains. The inhibitory N-terminal domain binds non-and B isoforms of PC5/6 are encoded by the same gene. The structure includes (1) the N-
ain, which maintains the inactive zymogen state of PCs and which also acts as an
xhibits an Asp-His-Ser catalytic triad and an additional Asn, (4) a barrel-like structured P
ne attachment sequences, a Cys-rich region and intracellular sorting signals.
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MMPs, blocking access of substrates to the catalytic site. The C-
terminal domain of TIMP-1 and TIMP-2 binds to the hemopexin
domain of the proenzymes of MMP-9 and MMP-2, respectively. The
latter binding is essential for the cell surface activation of MMP-2 by
MMP-14/MT1-MMP.
In this well-characterized unconventional activation mechanism,
MMP-14/MT1-MMP on the cell surface acts as a receptor for TIMP-2.
TIMP-2 binds via its N-terminal domain to the active site of MT1-
MMP. This binary complex then acts as a receptor for the MMP-2
proenzyme, with the TIMP-2 C-terminal domain binding to the C-
terminal hemopexin domain of MMP-2 and with the formation of a
trimolecular MT1-MMP–TIMP-2–MMP-2 complex. A TIMP-2-free,
second MT1-MMP molecule which is close to the trimolecular
complex then cleaves the N-terminal propeptide of the MMP-2
proenzyme, generating an intermediate species. Further proteolysis of
theMMP-2 propeptide through an autocatalytic mechanism generates
the fully active enzyme of MMP-2 which is then released from the
complex.
3. Structure and function of MT1-MMP
MT1-MMP, a prototypic membrane-type MMP, is distinguished
from soluble MMPs by a C-terminal transmembrane domain and a
cytoplasmic tail [4]. In the human genome, MT1-MMP is encoded by a
single copy gene located on chromosome 14. MT1-MMP is widely
expressed and its presence has been documented in multiple cell
types [17]. Because both the expression and the activity of MT1-MMP
are elevated in tumor cells and because high levels of MT1-MMP
directly correlate with enhanced cell migration, this proteinase is
generally considered pro-invasive and pro-tumorigenic.
Because the prodomain part of MT1-MMP has the furin-cleavage
motif, furin is an essential component of the activation pathway that
results in the generation of the active, mature cellular MT1-MMP
[11,18]. MT1-MMP was originally thought to exhibit a single function
as a membrane activator of soluble MMPs, including MMP-2 [19,20]
and MMP-13 [21]. Recent data, however, has provided evidence that,
in addition, MT1-MMP degrades multiple components of the
extracellular matrix and a number of cell adhesion and signaling
receptors [22]. MT1-MMP is regulated at the transcriptional and
post-transcriptional levels by multifaceted, tightly controlled and
well-coordinated mechanisms both as a proteinase and as a
membrane protein. These multidimensional mechanisms regulate
MT1-MMP spatially and temporally, and they are essential not only
for the proper functioning of MT1-MMP alone but also for the
performance of the normal multiple biological functions of the entire
cell. These mechanisms control the functional activity of cell surface-
associated MT1-MMP and they include control of the extent of
activation of the MT1-MMP proenzyme by furin, the level of
inhibition of MT1-MMP by TIMPs and self-proteolytic inactivation,
a homophilic complex formation involving the hemopexin domain
and the cytoplasmic tail, the efﬁciency of trafﬁcking of MT1-MMP
through the cell compartment to the plasma membrane, the rate of
the internalization of MT1-MMP into the transient compartment
inside the cells and, lastly, the extent of the recycling of MT1-MMP
back to the plasma membrane [17,22,23].
Internalization via clathrin-coated pits and also through caveolae
is also recognized as an important mechanism to regulate MT1-MMP
activity [24–27]. The “up/down” switch may have been built into the
peptide sequence of the MT1-MMP's cytoplasmic tail to regulate the
recruitment to the plasmamembrane and to target the protease to the
invasive front in migrating cells. Transient changes in subcellular
compartmentalization of MT1-MMP, which occur in its trafﬁcking and
internalization pathways, are, probably, the underlying mechanisms
which speciﬁcally control the functions of MT1-MMP in malignant
cells [28,29].TIMP-2, TIMP-3 and TIMP-4 are highly potent inhibitors of MT1-
MMP. TIMP-1, however, is a very poor inhibitor of MT1-MMP [5,16,30].
Current evidence suggests that the activity of cellular MT1-MMP is
short-lived and that the half-life of active, mature MT1-MMP attached
to the plasma membrane is approximately 1 h [29,31]. During this
time period, active MT1-MMP is either inactivated by TIMPs or
autolytically degraded or internalized with only a subsequent partial
recycling [32]. Because MT1-MMP, in addition to its role in matrix
degradation, is directly involved in the cleavage of cell surface
receptors, this short-lived proteinase, exerts a long-lasting effect on
cell behavior and functions in cancer cells as the main mediator of
proteolytic events on the cell surface. Evidence suggests that the
proteolysis of CD44, integrins, tissue transglutaminase, the low
density lipoprotein receptor-related protein (LRP1), E-cadherin and
related cell-associated adhesion signaling receptors is the important
role of MT1-MMP [22]. By cleaving these receptors, the short-lived
MT1-MMP has a long-lasting effect on the cell microenvironment and
cell behavior. In addition, MT1-MMP, as opposed to the soluble MMPs,
is ideally positioned to regulate pericellular proteolysis and the
functionality of the neighboring cell receptors, including CD44 [23].
CD44 is the most well-recognized target of MT1-MMP proteolysis in
tumor cells [33–37]. MT1-MMP acts as a processing enzyme for CD44,
releasing it into the medium as a soluble 70-kD fragment. This
processing event stimulates cell motility. In turn, expression of either
CD44 or MT1-MMP alone did not signiﬁcantly stimulate cell motility.
Co-expression of MT1-MMP and mutant CD44 lacking the MT1-MMP-
processing site did not result in shedding and did not promote cell
migration, suggesting that the processing of CD44 by MT1-MMP is
critical in the migratory stimulation. MT1-MMP forms a complex with
CD44 via the hemopexin domain and, as a result, CD44 acts as a linker
that connects MT1-MMP to the actin cytoskeleton and plays an
important role in directing MT1-MMP to the migration front.
Since the discovery of MT1-MMP in 1994–1995 and the ﬁndings
showing its role in the activation of MMP-2 there remains an
unanswered question: what is the mechanism of the activator's
activation? [19,20,38]. Volumes of data generated through the years
suggest thatMT1-MMP is a key player in tumor cell migration and that
MT1-MMP is a likely drug target inmultiple pathologies. A precise and
complete understanding of the activation and regulation mechanisms
of MT1-MMP is required for the design of effective therapies.
4. Proprotein convertases (PCs)
Furin and related proteases are specialized serine endoproteinases,
which cleave the multibasic motifs R-X-R/K/X-R and transform
proproteins into biologically active proteins and peptides [39,40].
Structurally and functionally, furin resembles its evolutionary pre-
cursor: the prohormone-processing kexin of yeast Saccharomyces
cerevisiae. The enzyme furin, which is encoded by the fur gene, was
the ﬁrst and can be considered the prototype of amammalian subclass
of subtilisin-like proteases. The localization of the gene immediately
upstream from the FES oncogene (V-FES feline sarcoma viral
oncogene homolog) generated the name FUR (for FES upstream
region). Furin is similar to other PCs in that it contains a signal peptide,
a prodomain, a subtilisin-like catalytic domain, a middle P domain, a
cysteine-rich region, a transmembrane anchor, and a cytoplasmic tail
(Figs. 1 and 2). Furin and PCs are normally N-glycosylated glycopro-
teins. Phosphorylation of the cytoplasmic tail is required for the trans-
Golgi localization of furin which in vivo exists as di-, mono- and non-
phosphorylated forms.
Furin is currently the most studied enzyme of this protease family.
Seven furin-family proteases (furin, PC1/3, PC2, PC4, PC5/6, PC7 and
PACE4) have been identiﬁed in humans [41]. Isozyme-1 (SKI-1) [42] or
Site1 Protease (S1P) (PCSK8) [43] (pyrolysin subfamily) and Neural
Apoptosis Regenerative Convertase-1 (NARC-1) or PCSK9 [44]
(proteinase K type) which cleave peptide bonds C-terminal to a
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expressed and it is primarily localized in the trans-Golgi network. A
proportion of the furin molecules cycles between the trans-Golgi and
the cell surface. Because of the overlapping substrate preferences and
cell/tissue expression, redundancy exists in the functionality of PCs in
vivo, although certain distinct functions of the individual members of
the family have been demonstrated. For example, furin knockout is
lethal in mice [45] attesting to its unique in vivo functions. Most of the
furin targets, including matrix metalloproteinases such as MT1-MMP,
growth factors, and adhesion molecules are essential in the processes
of cellular transformation, acquisition of the tumorigenic phenotype,
and metastases formation. Furin and other PCs are self-activated and,
as a result, they initiate the proteolytic cascade leading to the
activation of MT1-MMP and the downstream MMP-2 and MMP-13
[40]. Propeptide cleavage is a prerequisite for the exit of furin
molecules out of the endoplasmic reticulum. The second cleavage in
the propeptide occurs in the trans-Golgi network, which is followed
by the release of the propeptide bound to furin and the activation of
furin.
5. A “single-step” mechanism of MT1-MMP activation is not
completely correct
It is known that the R108RKR111↓Y112 motif of the prodomain
sequence of the latent MT1-MMP proenzyme is processed by furin
and several additional furin-like PCs in the course of the secretion
pathway and that this “single-step” processing results in the mature
enzyme commencing from N-terminal Y112 [18]. It is also well
established that the Cys residue of the prodomain cysteine-switch
motif maintains the latent status of the proenzyme by chelating the
active site zinc. The cysteine-switch sequence itself and the
prodomain inhibit MMPs including MT1-MMP. Experimental evi-
dence conﬁrms that the individual prodomain is a potent inhibitor of
MT1-MMP (Ki=200 nM).
A “single-step” mechanism suggests that the excised prodomain
likely remains associated with the mature proteinase and as a result,
inactivates the proteinase. Thus, following cleavage of the ADAM12
prodomain in the trans-Golgi by a furin proteinase, the prodomain
remains non-covalently associated with themature molecule [46]. We
know, however, that in contrast with ADAM12 the activated MT1-
MMP is free from its prodomain and, as a result, the mature enzyme
exhibits full proteolytic activity.
6. A two-step mechanism of MT1-MMP activation
To inactivate the excised inhibitory prodomain and to liberate the
processed active enzyme species from the prodomain's inhibition,
multiple members of the MMP family employ a two-step mechanism.
This mechanism involves the cleavage of the prodomain peptide
sequence both by an external proteinase and by autocatalysis. Based
on these considerations and on the conserved three-helix bundle
structure of the MMP prodomains, we now believe that, in addition to
a furin-dependent step, there is an additional and previously
uncharacterized step in the MT1-MMP activation process [47].
Accordingly, we believe that detecting and establishing the precise
nature and the N-terminal sequence of the activation intermediate(s),
which are generated as a result of the cleavage in the “bait” region of
the prodomain, will lead to a more complete understanding of the
activation mechanism of MT1-MMP.
The results of our recent biochemical studies support our
hypothesis [47]. In our study, we used synthetic peptides, the
recombinant prodomain and the soluble MT1-MMP constructs, the
furin-cleavage resistant MT1-MMP mutants and the MT1-MMP
mutants with the inactivated bait region cleavage sites. The
proteolytic processing of these constructs was analyzed by N-terminal
sequencing and MS of the resulting cleavage fragments. Our resultsprovide substantial evidence that supports a two-step mechanism of
MT1-MMP activation and prodomain sequence processing. Our results
suggest that there is a proteolytic processing of the bait region of the
prodomain sequence of MT1-MMP (either at the P47GD↓L50 or the
P58QS↓L61 or at both sites). This event results in the activation
intermediate of MT1-MMP, the presence of which we have demon-
strated using in vitro tests and cell-based assays. In agreement, the
processing of the prodomain by furin was impaired in the L50D/L61D
mutant inwhich both cleavage sites of the prodomain bait regionwere
inactivated by mutations. The step-wise activation of MT1-MMP also
involves the action of a furin proteinase cleaving the inhibitory
prodomain at the R108RKR111↓Y112 site, where Y112 is the N-terminal
residue of the mature MT1-MMP enzyme. This two-step mechanism
eventually leads to the degradation of the inhibitory prodomain and
the release of the activated, mature MT1-MMP enzyme.
7. TIMP-2 paradox in cancer
The TIMP-2 paradox we want to clarify arises from the fact that
TIMP-2 is a powerful inhibitor of the pro-invasive, pro-tumorigenic
MT1-MMP activity but, at the same time, high levels of TIMP-2
positively correlate with an unfavorable prognosis in cancer patients
[48–52]. In a manner counterintuitive to the conventional thinking, it
was recently demonstrated that in addition to extracellular proteo-
lysis, the MT1-MMP•TIMP-2 interactions control cell functions
through a non-proteolytic mechanism [53]. TIMP-2 (but not structu-
rally similar TIMP-1) binding to MT1-MMP induces, in a matter of
minutes, an intracellular ERK1/2 signaling cascade. The induction of
the ERK cascade was observed only at the physiologically-relevant,
low concentrations of TIMP-2. Excessively high, abnormal concentra-
tions of TIMP-2 (1–5 μg/ml or 50–250 nM) were used in cell systems
previously [54–59] and these concentrations are multi-fold higher
than the 10–100 ng/ml (0.5–5 nM) range recorded for tissues and
biological ﬂuids [60–63]. As a result, the signaling function of the
MT1-MMP•TIMP-2 complex were overlooked and remained
unidentiﬁed.
8. MT1-MMP•TIMP-2-dependent signaling
Our group jointly with Dr. P. Mignatti (New York University) [53]
demonstrated that very low, physiological, concentrations of TIMP-2
stimulate, in a dose-dependent and MT1-MMP-dependent manner,
the rapid activation of the downstream Ras-Raf-ERK signaling cascade
leading to a burst in cancer cell migration. When compared to the
MT1-MMP-deﬁcient breast carcinoma MCF7 control, the proteolyti-
cally inert mutant MT1-MMP E240A construct also stimulated the
Ras-Raf-ERK signaling cascade and promoted cell migration in the
presence of physiological concentrations of TIMP-2. This TIMP-2-
dependent stimulation, however, was less efﬁcient than which we
observed with the wild-type MT1-MMP construct. In turn, in the
presence of TIMP-2 the tailless MT1-MMP that lacked the C-terminal
cytoplasmic tail did not stimulate the Ras-Raf-ERK cascade and did not
promote cell migration. The C-terminal PEX domain (but not the
catalytic domain) of the inert mutant binds TIMP-2 — this important
discovery was clearly described in our recent paper [53]. This binding
mode is similar to that of the proMMP-2•TIMP-2 complex inwhich the
MMP-2's PEX domain (but not the catalytic domain) binds the
inhibitor's C-terminal domain. In contrast with TIMP-2, the binding of
GM6001 (a small-molecule active site inhibitor) cannot stimulate the
ERK signaling pathway. The Ala-N end-appended TIMP-2 with the
inactivated N-terminal inhibitory domain also induces the ERK
signaling, suggesting again that binding of the C-terminal domain of
TIMP-2 with the PEX domain of MT1-MMP is required for signaling
[53]. Overall, the data suggested, for the ﬁrst time, the presence of the
non-proteolytic mechanisms involving MT1-MMP and TIMP-2 in the
regulation of cell migration.
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naturally express MT1-MMP
To demonstrate that the MT1-MMP•TIMP-2-dependent signaling
has physiological relevance, ﬁbrosarcoma HT1080 cells, which express
MT1-MMP naturally, were studied in addition to the stably trans-
fected, MT1-MMP-overexpressing cells (Sounni et al., manuscript in
preparation). In this study, the expression of MT1-MMP was
transcriptionally silenced by using the MT1-MMP siRNA and the
generated MT1-MMP-siRNA cells were used as a control. As an
additional control, siRNAscr cells, which were transfected with the
scrambled siRNA construct were isolated. Immunoblotting conﬁrmed
the near complete repression of MT1-MMP in MT1-MMP-siRNA cells.
In turn, the scrambled siRNA did not have any signiﬁcant effect on
MT1-MMP. Consistent with the presence of MT1-MMP on cell
surfaces, only siRNAscr and parental cells activated MMP-2. Because
of the silencing of MT1-MMP, MT1-MMP-siRNA cells did not activate
MMP-2. Consistent with the silencing of MT1-MMP, the migration
efﬁciency of MT1-MMP-siRNA cells was reducedwhen comparedwith
both parental HT1080 and siRNAscr cells. In the absence of the
externally added TIMP-2, inhibition of MT1-MMP by GM6001
decreased the migration efﬁciency of the original HT1080 and
siRNAscr cells to the levels we recorded with the untreated MT1-
MMP-siRNA cells. In turn, GM6001 did not cause any additional
suppression in MT1-MMP-siRNA cells.
The physiological concentrations of TIMP-2 (50–100 ng)were used
to stimulate ERK signaling in HT1080 cells. A 15-min co-incubation
with TIMP-2 (100 ng/ml) was sufﬁcient to induce ERK1/2 phosphor-
ylation in siRNAscr cells. GM6001 did not reverse the stimulatory
effect of TIMP-2 on phosphorylation of ERK1/2 in siRNAscr cells. In
contrast with pERK1/2, TIMP-2 did not affect the levels of both pSrc
and total Src in both MT1-MMP-siRNA and siRNAscr cells, thus
supporting the speciﬁc activation of the ERK pathway. As expected,
TIMP-2 did not induce any signiﬁcant activation of ERK1/2 in MT1-
MMP-siRNA cells in which the expression of MT1-MMP was
transcriptionally silenced. As a result of TIMP-2 binding with cell
surface-associated, naturally producedMT1-MMP and the subsequent
stimulation of the intracellular signaling, the levels of pMEK1/2 that
are directly upstream of ERK1/2, pERK1/2 itself and of the ERK1/2
substrate p-p90RSK transcriptional factor increased in HT1080 cells.
Importantly, the TIMP-2/MT1-MMP-mediated signal generated a
signiﬁcant, 2–3-fold, increase in the levels of pMEK/pERK in the cells,
thus suggesting that the primary role of the TIMP-2•MT1-MMP
interactions is in the activation of ERK. TIMP-2 did not induce the ERK/
MEK pathway in the cells which exhibited a low level of MT1-MMP
(e.g., MT1-MMP-deﬁcient breast carcinoma MCF-7 cells). The small-
molecule inhibitor GM6001 did not reverse TIMP-2•MT1-MMP-
mediated stimulation of theMEK–ERK–p90RSK cascade. In agreement
with the known pro-migratory function of activated ERK, TIMP-
2•MT1-MMP-dependent stimulation of intracellular signaling pro-
motes cell migration of siRNAscr cells but not MT1-MMP-siRNA cells.
U0126 (an inhibitor of MEK/ERK) reversed the stimulatory effect of
TIMP-2 on pMEK1/2, pERK1/2 and cell migration in siRNAscr cells,
while GM6001 alone or in combination with 100 ng/ml TIMP-2 had
no signiﬁcant effect on MEK and ERK.
10. MT1-MMP's PEX binds TIMP-2 similar to PEX in the MMP-2
proenzyme–TIMP-2 complex
Current data regarding the TIMP-2•MT1-MMP-dependent stimula-
tion of intracellular signaling agree well with the mechanism inwhich
the C-terminal domain of TIMP-2 binds directly with the PEX domain
of MT1-MMP. This binding is in addition to the binding of the catalytic
domain of MT1-MMPwith the N-terminal inhibitory domain of TIMP-
2. It appears that the PEX-binding mode of MT1-MMP by TIMP-2 is
required for the intracellular signalingmediated by the resultingMT1-MMP•TIMP-2 complex. There is solid evidence that this binding mode
takes place in the formation of TIMP-2's complex with proMMP-2
[10,19,64]. Because of the high homology between the PEX domains of
MMP-2 and MT1-MMP, it is probable that there is a structural
rationale for a similar interaction of TIMP-2 with MT1-MMP.
11. The importance of a proteolysis-independent mechanism in
orthotopic breast cancer xenograft growth
The biological signiﬁcance of the proteolysis-independent
mechanisms involving MT1-MMP was recently validated by evaluat-
ing the growth of tumor xenografts expressing the wild-type or
mutant MT1-MMP constructs [53]. For this purposeMCF-7 cells stably
transfected with the wild-type MT1-MMP or mutant MT1-MMP
devoid of proteolytic activity (E240A) or cytoplasmic tail (ΔCT), or
mock transfected were xenografted into the fad pads of immunodeﬁ-
cient mice. Tumor xenografts expressing the wild-type MT1-MMP or
proteolytically inert, E240A MT1-MMP grew to a size that greatly
exceeded that of tumors expressing no MT1-MMP or MT1-MMP
devoid of the cytoplasmic tail, both of which could not elicit the
signaling cascade. At day 130 post-implantation there was an over 20-
fold size difference between tumors expressing the wild-type MT1-
MMP and tumors derived from mock transfected cells. The volume of
tumors expressing proteolytically inactive MT1-MMP was 50% that of
wt MT1-MMP-expressing tumors. In contrast, tumors derived from
cells expressing the tailless, non-signaling MT1-MMP construct were
no different in size from those derived from control, empty vector-
transfected, cells.
12. LRP1
Low density lipoprotein-related protein 1 (α2-macroglobulin
receptor), also known as CD91, is a cell receptor found in the plasma
membrane of human cells involved in receptor-mediated endocytosis.
LRP1 is a multifunctional receptor that binds and endocytoses
multiple structurally and functionally distinct ligands including
MMP-2 and MMP-9 [65–69]. Cellular LRP1 consists of a non-
covalently associated 515 kDa extracellular α-chain (LRP-515) and
an 85 kDa membrane-spanning β-chain (LRP-85), and it plays a dual
role as a multifunctional endocytic receptor and a signaling molecule.
The functionality of LRP1 and the subsequent uptake of its ligands by
malignant cells are both regulated by MT1-MMP proteolysis of the C-
terminal part of the LRP-515 subunit [27,31,67,70]. Because LRP1 is
essential for the clearance of multiple ligands, these ﬁndings have
important implications for many pathophysiological processes includ-
ing the pericellular proteolysis in neoplastic cells as well as the fate of
the soluble, matrix-degrading proteases such as MMP-2 and MMP-9
[65,66,71–74]. LRP1 associates with the MT1-MMP's catalytic domain
and is highly susceptible to MT1-MMP proteolysis in vitro. Similar to
MT1-MMP, related MT2-, MT3- and MT4-MMPs also degrade LRP1. In
cells co-expressing LRP1 and active MT1-MMP, the proteolytically
competent protease decreases the levels of cellular LRP1 and releases
its N-terminal portion in the extracellular milieu while the catalyti-
cally inert protease co-precipitates with LRP1. These events implicate
MT1-MMP (an activator of MMP-2) in the mechanisms which control
the clearance and the fate of MMP-2 and MMP-9 in cells/tissues [67].
It should be mentioned that Alzheimer-related γ-secretase activity
that cleaves amyloid precursor protein (APP) also attacks the
transmembrane domain of LRP1 [75]. This cleavage releases the
cytoplasmic domain fragments of LRP1 which are further translocated
to the nucleus and act as transcription modulators [76]. The soluble
cytoplasmic tail of LRP1 without a membrane tether is sufﬁcient to
promote amyloid beta (Abeta) protein generation [77]. If LRP1
processing occurs like Notch processing [78], the shedding of the
ectodomain is an initial requirement, and MT1-MMP may be
responsible for initiating this event. In addition, LRP1 is known to
139A.Y. Strongin / Biochimica et Biophysica Acta 1803 (2010) 133–141associate with APP [79,80] and, furthermore, LRP1 is genetically
associated with Alzheimer's disease [81]. MT1-MMP also cleaves APP
and releases its truncated soluble form that is deﬁcient in the
inhibitory activity against MMP-2 [82]. If MMP-2 itself cleaves APP,
the released APP fragment subsequently inactivates the MMP-2
enzyme in a manner similar to TIMPs [83]. Apparently, there is a
general similarity in the functional role that MT1-MMP plays acting
against APP and LRP1: in both cases this membrane-tethered
protease protects the MMP-2 activity from inactivation by inhibition
or, similarly, by internalization. In addition, these combined data
suggest that APP, LRP1, MT1-MMP and presenilin γ-secretase, reside
and act at the plasma membrane in close proximity with each other
and that presenilin γ-secretase is the next likely target of MT1-MMP
proteolysis.
13. MT1-MMP•TIMP-2•LRP1?
It is highly likely that MT1-MMP itself cannot signal because its
cytoplasmic tail is exceedingly short, because it does not exhibit any
unusual sequences which are additional to the internalization signals
and because the cytoplasmic tail-binding adaptor proteins have not
been reliably identiﬁed [84]. It may well be that an interaction of the
MT1-MMP•TIMP-2 with a cellular signaling receptor is required to
elicit the signaling through the latter.
It is tempting to hypothesize that the low density lipoprotein-
related receptor protein-1 (LRP1)may ﬁt this signaling receptor shoes.
Active MT1-MMP cleaves LRP1 but if MT1-MMP is inhibited by TIMP-
2, the MT1-MMP•TIMP-2 inactive complex binds, but does not cleave,
the LRP1 receptor. It is possible that as a result of this binding event,
LRP1 signals through its long, heavily phosphorylated cytoplasmic tail.
LRP1 signaling is well known to stimulate the ERK/MEK pathway
[72,85–89]. The MT1-MMP•TIMP-2•LRP1 complex is then internalized
by the cells causing a decay of the signal. Other mechanisms, however,
can be involved and these mechanisms can also explain, albeit
vaguely, why MT1-MMP•TIMP-2-dependent signaling is not observed
at high concentrations of TIMP-2.
In contrast with both thewild-typeMT1-MMP and LRP1, which are
not continuously associated with the caveolin-enriched lipid rafts
[90], the tailless ΔCT MT1-MMP mutant, as we demonstrated earlier
[27], is always localized in the lipid rafts and, as a result, this mutant
cannot access LRP1 and cause LRP1-dependent ERK signaling. The
invasion-promoting, non-proteolytic function of theMT1-MMP•TIMP-
2•LRP1 complex results in the activation of ERK and this function is
novel, additional and distinct from the proteolytic function of MT1-
MMP that requires cleavage of the target proteins.
Intriguingly, given that this hypothesis is correct, the functioning of
the MT1-MMP•TIMP-2•LRP1 system appears similar to the urokinase-
type plasminogen activator•urokinase receptor•plasminogen activator
inhibitor type-1•LRP1 (uPAR•uPA•PAI-1•LRP1) system and to the PAI-1
paradox in cancer [91–93]. It is generally assumed that a pro-
malignant effect of the uPA–uPAR system is mediated by increased
local proteolysis thus favoring tumor invasion, by a pro-angiogenic
effect of this system and also by uPA–uPAR signaling towards the
tumor thereby shifting the tumor phenotype to a more malignant one.
When tumor patients are analyzed for long term survival, those with
high levels of the PAI-1 inhibitor have a much worse prognosis than
those with low PAI-1 levels. In a manner similar to MT1-MMP•TIMP-2,
this indicates that increased overall proteolysis alone is not respon-
sible for the adverse effects of either the plasminogen-activating
system or the MT1-MMP system in tumors. It is clear that additional
studies are required to precisely establish the role of LRP1 in the MT1-
MMP•TIMP-2-dependent signaling.
If the hypothesis that the activation of the ERK pathway involves
theMT1-MMP•TIMP-2•LRP1 axis rather thanMT1-MMP•TIMP-2 alone
is experimentally validated, these results will serve as a paradigm shift
in the current understanding of the MT1-MMP and TIMP-2 function-ality and as a foundation for a novel and effective cancer therapy. This
therapy will target the signal streaming from the MT1-MMP•TIMP-
2•LRP1 complex inside the cells.
The existence of the MT1-MMP•TIMP-2•LRP1 cascade in cancer
cells may explain a direct rather than an inverse association of TIMP-2
with a poor prognosis in cancer. Because evidence now suggests that
the signaling, non-proteolytic function of MT1-MMP and the MT1-
MMP•TIMP-2•LRP1-mediated signaling play a signiﬁcant role in
cancer by stimulating invasion and migration of malignant cells, we
strongly believe that follow-on in-depth studies are urgently required.
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